LEADER 04757nam 2201285z- 450 001 9910557794803321 005 20210501 035 $a(CKB)5400000000045439 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68373 035 $a(oapen)doab68373 035 $a(EXLCZ)995400000000045439 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNew Prognostic and Predictive Markers in Cancer Progression 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (294 p.) 311 08$a3-03943-977-4 311 08$a3-03943-978-2 330 $aBiomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient's outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of "multiomics" data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types. 606 $aMedicine and Nursing$2bicssc 610 $aacetyltransferase 610 $aAKT 610 $aantigen processing machinery (APM) molecules 610 $aAR 610 $abiomarker 610 $abiomarkers 610 $abladder cancer 610 $ablood 610 $aBRCA1/2 610 $abreast cancer 610 $acancer 610 $acancer immunotherapy 610 $acancer prognosis 610 $acarcinogenesis 610 $acardioncology 610 $acardiotoxicity 610 $acastration-resistant prostate cancer (CRPC) 610 $aCD8+ T effector cells 610 $achemo-/radio resistance 610 $aCSC 610 $aCTCs 610 $acytokines 610 $aEMT 610 $aeribulin 610 $agenetic syndromes 610 $agenomic mutations 610 $ahead and neck cancer 610 $ahead and neck neoplasms 610 $ahead and neck tumors 610 $aHRR 610 $aHUB nodes 610 $ahuman leukocyte antigen (HLA) 610 $ahyperglycemia 610 $aimmune checkpoint inhibitor 610 $aK-RAS oncogene 610 $alaryngeal cancer 610 $alifestyle habit 610 $amajor histocompatibility complex (MHC) 610 $aMAPK 610 $amelanoma 610 $amelanoma resistance to MAPK/MEK inhibitors 610 $ametabolomics 610 $ametastasis 610 $amicroRNA 610 $amiRNA 610 $aMSI2 610 $amTOR 610 $amusashi 2 610 $amutations 610 $aN-cadherin 610 $an/a 610 $aNAA10 610 $anew metastasis 610 $anivolumab 610 $aoncogene dependency 610 $aoral cancer 610 $aOSCC 610 $apancreatic cancer 610 $aparaganglioma 610 $aPDL1 610 $apheochromocytoma 610 $aPI3K 610 $aPI3KCA 610 $aprediction 610 $aprognosis 610 $aprostate cancer 610 $aPTEN 610 $aresistance to immune checkpoint inhibitors 610 $aselenoproteins 610 $atargeted therapies 610 $atherapeutic resistance 610 $atherapeutic target 610 $aTILs 610 $aTNBC 610 $atranscriptomics 610 $atumor predisposition 610 $aWNT 615 7$aMedicine and Nursing 700 $aCostantini$b Susan$4edt$01324162 702 $aBudillon$b Alfredo$4edt 702 $aCostantini$b Susan$4oth 702 $aBudillon$b Alfredo$4oth 906 $aBOOK 912 $a9910557794803321 996 $aNew Prognostic and Predictive Markers in Cancer Progression$93035971 997 $aUNINA